These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 35639332)

  • 21. Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
    Wallace D; Reagan PM
    Drugs; 2021 Apr; 81(6):669-684. PubMed ID: 33783717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for mantle cell lymphoma.
    Smolewski P; Witkowska M; Robak T
    Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment for mantle cell lymphoma].
    Izutsu K
    Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
    Burkart M; Karmali R
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
    Abramson JS; Ghosh N; Smith SM
    Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.
    Al-Mansour M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1019-e1031. PubMed ID: 36068158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
    Villa D; Jiang A; Visco C; Crosbie N; McCulloch R; Buege MJ; Kumar A; Bond DA; Paludo J; Maurer MJ; Thanarajasingam G; Lewis KL; Cheah CY; Baech J; El-Galaly TC; Kugathasan L; Scott DW; Gerrie AS; Lewis D
    Blood Adv; 2023 Aug; 7(16):4576-4585. PubMed ID: 37307169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dismantling relapsed/refractory mantle cell lymphoma.
    Ryan CE; Kumar A
    Blood Rev; 2024 Jun; ():101221. PubMed ID: 38906740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment strategies in mantle cell lymphoma.
    Maddocks K; Blum KA
    Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
    Atilla E; Atilla PA; Demirer T
    Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.
    Munshi PN; Hamadani M; Kumar A; Dreger P; Friedberg JW; Dreyling M; Kahl B; Jerkeman M; Kharfan-Dabaja MA; Locke FL; Shadman M; Hill BT; Ahmed S; Herrera AF; Sauter CS; Bachanova V; Ghosh N; Lunning M; Kenkre VP; Aljurf M; Wang M; Maddocks KJ; Leonard JP; Kamdar M; Phillips T; Cashen AF; Inwards DJ; Sureda A; Cohen JB; Smith SM; Carlo-Stella C; Savani B; Robinson SP; Fenske TS
    Transplant Cell Ther; 2021 Sep; 27(9):720-728. PubMed ID: 34452722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Arcari A; Morello L; Vallisa D; Marcheselli L; Tecchio C; Quaglia FM; Tisi MC; Zilioli VR; Di Rocco A; Perrone T; Gini G; Dogliotti I; Bianchetti N; Bozzoli V; De Philippis C; Alvarez De Celis MI; Chiappella A; Fabbri A; Pelosini M; Merli M; Molinari AL; Sciarra R; Volpetti S; Hohaus S; Nassi L; Visco C
    Leuk Lymphoma; 2021 Dec; 62(14):3474-3483. PubMed ID: 34625013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
    Davis DD; Ohana Z; Pham HM
    J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.